GlaxoSmithKline's effort to relaunch cancer R&D faces skepticism

GlaxoSmithKline ($GSK) made a high-profile decision to exit the cancer drug field in its recent deal with Novartis ($NVS), but as Reuters reports, a band of specialists inside GSK still has ambitious plans for developing next-gen therapies. GSK is concentrating its hopes on bispecific antibodies and immuno-oncology, which has emerged as the hottest field in drug R&D. Still, the pharma giant is likely to run into considerable skepticism. "It's hard to envision GSK spending a lot of money in an area in which they no longer have a commercial presence," Marshall Gordon, healthcare analyst for ClearBridge Investments, tells Reuters. Story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.